

Boston Scientific

Boston Scientific Names Leading Electrophysiologist to Its Medical Team

PRNewswire
NATICK, Mass.
(NYSE:BSX)

NATICK, Mass., Aug. 31 [/PRNewswire-FirstCall/](#) -- Boston Scientific Corporation (NYSE: BSX) today announced that Ken Stein, M.D., FACC, will join the Company as Senior Vice President and Associate Chief Medical Officer for its Cardiac Rhythm Management (CRM) group. Dr. Stein is currently the Associate Director of Clinical Cardiac Electrophysiology at Weill Cornell Medical Center and Associate Professor of Medicine at Cornell University.

"We are excited that Dr. Stein is joining our team," said Fred Colen, President, Boston Scientific CRM. "His extensive clinical and research experience, coupled with his broad knowledge of cardiac rhythm management, will make him a strong contributor to the development of our medical technology."

"Dr. Stein will be an extremely valuable addition to the Company's medical leadership team," said Donald S. Baim, M.D., Chief Medical and Scientific Officer of Boston Scientific. "I know he will play a key role in our ongoing efforts to provide CRM patients the most innovative products and therapies."

Dr. Stein will oversee the development and execution of clinical strategy for the Company's CRM group.

He is a Phi Beta Kappa graduate of Harvard College, and he earned his M.D. from New York University School of Medicine. He completed his medical internship and residency at The New York-Presbyterian Hospital/Weill Cornell Medical Center, where he also completed his cardiology and electrophysiology training. He has published widely in the areas of cardiac electrophysiology with special interest in cardiac resynchronization therapy.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our product performance, clinical outcomes, regulatory approval of our products, and our growth strategy. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A- *Risk Factors* in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - *Risk Factors* in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

508-650-8541 (office)
508-667-5165 (mobile)
Media Relations
Boston Scientific Corporation

Larry Neumann
508-650-8696 (office)
Investor Relations
Boston Scientific Corporation

SOURCE Boston Scientific Corporation

SOURCE: Boston Scientific Corporation

Web site: <http://www.bostonscientific.com/>

<https://stage.mediaroom.com/bostonscientific/leading-electrophysiologist-ken-stein>